| 000 | 01813 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518091009.0 | ||
| 264 | 0 | _c20210107 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1879-0712 | ||
| 024 | 7 |
_a10.1016/j.ejphar.2020.173050 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMehrpouri, Mahdieh | |
| 245 | 0 | 0 |
_aAnti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity. _h[electronic resource] |
| 260 |
_bEuropean journal of pharmacology _cMay 2020 |
||
| 300 |
_a173050 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aAutophagy _xdrug effects |
| 650 | 0 | 4 |
_aBortezomib _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEpigenesis, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aG1 Phase _xdrug effects |
| 650 | 0 | 4 |
_aGene Expression Regulation, Leukemic _xdrug effects |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNF-kappa B _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPanobinostat _xpharmacology |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aVincristine _xpharmacology |
| 700 | 1 | _aSafaroghli-Azar, Ava | |
| 700 | 1 | _aPourbagheri-Sigaroodi, Atieh | |
| 700 | 1 | _aMomeny, Majid | |
| 700 | 1 | _aBashash, Davood | |
| 773 | 0 |
_tEuropean journal of pharmacology _gvol. 875 _gp. 173050 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejphar.2020.173050 _zAvailable from publisher's website |
| 999 |
_c30713395 _d30713395 |
||